RPG Life Sciences Share Price Touches 52-Week High as Company Partners With Archerchem for Naprosyn ES Launch

The RPG Life Sciences share price touched a fresh 52-week high on Monday, 13 July 2026, in a session marked by broad-based buying interest in the counter, after the pharmaceutical company announced a partnership with Archerchem Healthcare to launch a Naproxen and Esomeprazole combination product, branded Naprosyn ES, for the first time in the Indian market.

The launch strengthens RPG Life Sciences‘s existing business relationship with Archerchem Healthcare. The RPG Life Sciences stock was quoting at Rs 2,877.00, up Rs 22.50 or 0.79 percent, after touching an intraday high of Rs 2,950.00, matching its 52-week high, before easing slightly to a low of Rs 2,820.45 during the session.

Click Here – Get Free Investment Predictions

RPG Life Sciences Share Price: Naprosyn ES Launch Details

The combination of Naproxen, a widely used non-steroidal anti-inflammatory drug, with Esomeprazole, a proton pump inhibitor that helps protect the stomach lining, addresses a common clinical need for pain management with reduced gastrointestinal risk. Fixed-dose combinations of the RPG Life Sciences share price growth story typically require less time for physicians to prescribe confidently, since the gastroprotective component is already built into the formulation rather than requiring a separate prescription and patient compliance for a second medication.

Parameter	Detail
Partner	Archerchem Healthcare
Product	Naprosyn ES, a Naproxen and Esomeprazole combination
Market status	First-time launch in India
Current price	Rs 2,877.00 (+0.79%)
52-week high	Rs 2,950.00 (touched intraday)
Intraday low	Rs 2,820.45

Trading volumes for the RPG Life Sciences share price stood at 3,302 shares against the five-day average of 3,828 shares, a decrease of 13.74 percent, indicating the positive reaction has been steady rather than driven by an unusually large surge in institutional buying.

Why the Archerchem Partnership Matters for the RPG Life Sciences Share Price

1. First-to-Market Combination Product

Launching a Naproxen and Esomeprazole combination for the first time in India gives RPG Life Sciences an early-mover advantage in this specific therapeutic combination, which can support premium pricing and brand loyalty before competitors introduce similar formulations. First-mover status in a specific combination category can be particularly valuable in the Indian pharmaceutical market, where physician prescribing habits, once established, tend to be sticky and can create a durable moat against later entrants.

2. Strengthening an Existing Business Relationship

The company specifically noted this launch strengthens its existing relationship with Archerchem Healthcare, suggesting a track record of successful collaboration that could pave the way for further joint product launches in the future, further supporting the broader product pipeline narrative behind the RPG Life Sciences share price story.

3. Addressing an Underserved Pain Management Segment

Combination products that pair an anti-inflammatory with gastric protection address a genuine clinical gap, since NSAID use is often limited by gastrointestinal side effects. Products that mitigate this risk while retaining efficacy can capture meaningful share in the broader pain management category. Chronic pain conditions, including arthritis and musculoskeletal disorders, often require prolonged NSAID use, making gastric protection a meaningful clinical consideration rather than a marginal add-on feature for many patients.

Get Pharmaceutical Sector Stock Guidance from a SEBI-Registered Investment Advisor

What Should Investors Watch in the RPG Life Sciences Share Price Now

Investors tracking the RPG Life Sciences share price should watch the initial market uptake of Naprosyn ES over the coming quarters, along with any expansion of the product into additional dosage forms or therapeutic line extensions that could broaden its addressable market within India’s pain management segment.

Given that the stock touched a fresh 52-week high on this news, investors should also watch whether the RPG Life Sciences share price can sustain above this level in subsequent sessions, since a failure to hold new highs can sometimes trigger short-term profit booking from investors who bought into the initial rally. Historically, stocks that break out to new highs on genuine business catalysts, rather than pure speculation, tend to hold their gains better than those driven by short-term momentum alone.

Download the Univest iOS App or Univest Android App to track the RPG Life Sciences share price live and get daily stock recommendations.

Conclusion

RPG Life Sciences’ new partnership with Archerchem Healthcare to launch Naprosyn ES, a first-of-its-kind Naproxen and Esomeprazole combination in India, has pushed the RPG Life Sciences share price to a fresh 52-week high of Rs 2,950.00 today. The launch further reinforces the company’s product pipeline and its existing partner relationships in the pharmaceutical space. Investors should track early product uptake and consult a SEBI-registered advisor before making investment decisions.

Frequently Asked Questions FAQs

Why did the RPG Life Sciences share price hit a 52-week high today?

Ans. The RPG Life Sciences share price touched a 52-week high of Rs 2,950.00 after the company announced a partnership with Archerchem Healthcare to launch Naprosyn ES, a Naproxen and Esomeprazole combination, for the first time in India.

What is Naprosyn ES?

Ans. Naprosyn ES is a combination product of Naproxen, an anti-inflammatory drug, and Esomeprazole, a proton pump inhibitor that helps protect the stomach lining, being launched for the first time in the Indian market.

Who is RPG Life Sciences partnering with for this launch?

Ans. RPG Life Sciences is partnering with Archerchem Healthcare to launch Naprosyn ES, strengthening its existing business relationship with the company.

How much did the RPG Life Sciences share price gain today?

Ans. The RPG Life Sciences share price gained 0.79 percent to Rs 2,877.00, after touching an intraday high of Rs 2,950.00, matching its 52-week high.

Why is a combination product like Naprosyn ES significant?

Ans. Combination products pairing an anti-inflammatory drug with gastric protection address a common clinical need, since NSAID use is often limited by gastrointestinal side effects.

Should investors buy RPG Life Sciences after this 52-week high?

Ans. Investors should track early product uptake and whether the stock sustains above its new high, and consult a SEBI-registered investment advisor before making investment decisions.